What's being said about HTDS, my man

MYMAN still believes in HTDS and that we'll see this stock in the 0.05 to 0.10 cent range by the end of the year. Here are some articles and blog posts about HTDS that you may find of interest, my man:

"The fact of the matter is that HTDS is a pretty safe company. While it has experienced some unusually high volatility in recent weeks, its consistent stability over the past several years should, for the most part, put investors' minds at ease. While it has been extremely volatile in August thus far, fluctuating from very large gains/losses to miniscule ones, it is fairly certain that a new support level has been formed out of it."

http://investmentessentials.blogspot.com/2009/08/htds-stock-review.html


"Keep an eye on her the next few weeks. HTDS could very well breakout in a big way."

http://stockbb.net/2009/08/27/htds-another-12-gain-today

"What I find compelling is that HTDS has done some very astute things (acquisition of Mellow Hope) and appears to be very cost efficient in searching for new products. I will be very interested to see what kind of numbers Mellow Hope can produce for the company going forward. The Serbian operation holds out great hope for the company, too. It is working on modifications to a number of existing drugs to treat some of the more “popular” diseases of today’s society. Working with existing drugs also means that the dreaded FDA turndown is less likely and drugs can be brought to market quicker."

http://www.microstockprofit.com/2009/08/24/hard-to-get-a-read-on-htds

"Shenzhen Mellow Hope Pharm Industrial Co., a subsidiary of Hard to Treat Diseases [Pink Sheets: HTDS], has reached an agreement to be the sole international distributor of a Recombinant Hepatitis B vaccine manufactured by North China Pharmaceutical Group (see story). NCPC is a large state-owned pharmaceutical company, with a specialty in vaccines."

http://seekingalpha.com/article/156355-china-biotech-in-review-the-business-of-china-life-science